Preconception Counseling — MCQs
What is the recommended dose of folic acid for a patient with a history of neural tube defect (NTD) in a previous pregnancy?
Which of the following values is MOST accurate for the recommended dietary allowance during pregnancy?
A female patient of childbearing age is on valproate for JME. Which drug should be used to replace valproate and can be prescribed as monotherapy?
Use of folic acid to prevent congenital malformations should be best initiated:
A pregnant woman is diagnosed with Graves' disease. The most appropriate therapy for her would be:
Which of the following conditions is least likely to be inherited in a familial manner?
After taking MMR live vaccine, conception should not occur within ?
34 week primigravida punjabi khatri comes with history of consanguineous marriage, with history of repeated blood transfusion to her sibling since 8 months of age. The first diagnostic test is -
A woman presents with a history of recurrent abortions at 8,11 , and 22 weeks, with normal fetal cardiac activity in all three pregnancies. She also has a history of preeclampsia in her last pregnancy. What is the most probable cause?
A 24-year-old woman presents with abnormal vaginal discharge. Wet mount shows motile trichomonads. Her male partner is asymptomatic. Which of the following is the most appropriate management for her partner?
Preconception Counseling Indian Medical PG Practice Questions and MCQs
Question 1: What is the recommended dose of folic acid for a patient with a history of neural tube defect (NTD) in a previous pregnancy?
- A. 0.5 mg
- B. 1 mg
- C. 2 mg
- D. 4 mg (Correct Answer)
Explanation: ***4 mg*** - For women with a prior history of a **neural tube defect (NTD)-affected pregnancy**, a higher dose of **4 mg of folic acid daily** is recommended to significantly reduce the risk of recurrence. - This increased dosage is crucial for achieving adequate maternal folate levels to prevent NTDs, starting at least one month before conception and continuing through the first trimester. *0.5 mg* - This dose is lower than the standard recommendation for women without a history of NTDs and is insufficient for high-risk individuals. - Suboptimal folic acid levels can still lead to a higher risk of NTD recurrence in patients with a history of NTD-affected pregnancies. *1 mg* - While 1 mg is higher than the general recommendation, it is still insufficient for women with a **history of NTD in a previous pregnancy**. - Current guidelines suggest a significantly higher dose for secondary prevention due to altered folate metabolism or higher requirements in these individuals. *2 mg* - This dose is also lower than the **established recommendation for high-risk women** who have had a previous NTD-affected pregnancy. - It does not provide the optimal level of protection required to reduce the risk of recurrence effectively.
Question 2: Which of the following values is MOST accurate for the recommended dietary allowance during pregnancy?
- A. 30 mg iron (Correct Answer)
- B. 500 µg folic acid
- C. 350 kcal additional energy
- D. 310 mg magnesium
Explanation: ***30 mg iron*** - The recommended daily allowance for **iron** during pregnancy is **27 mg/day** according to ACOG and dietary guidelines. - **30 mg iron** is the **closest value** to the actual recommendation among all options provided and is within the therapeutically accepted range for iron supplementation. - Iron supplementation is crucial during pregnancy to prevent iron-deficiency anemia due to increased maternal blood volume and fetal iron demands. *350 kcal* - Additional **caloric intake** recommendations during pregnancy are approximately **340 kcal/day in the second trimester** and **452 kcal/day in the third trimester**. - While 350 kcal is reasonably close to the average, it's less precisely aligned with specific trimester recommendations compared to the iron value. *500 µg folic acid* - The recommended daily intake of **folic acid** during pregnancy is **600 µg/day** to prevent neural tube defects. - **500 µg is below the RDA** by 100 µg (approximately 17% less than recommended), making this an inadequate supplementation level. *310 mg magnesium* - The recommended daily allowance for **magnesium** during pregnancy is typically **350-360 mg/day**. - **310 mg is significantly below the RDA** (approximately 40-50 mg less than recommended), making this the least accurate option among all choices.
Question 3: A female patient of childbearing age is on valproate for JME. Which drug should be used to replace valproate and can be prescribed as monotherapy?
- A. Carbamazepine
- B. Phenytoin
- C. Levetiracetam (Correct Answer)
- D. Zonisamide
Explanation: ***Levetiracetam*** - **Levetiracetam** is recommended as a safer alternative to valproate in women of childbearing potential due to its **favorable pregnancy safety profile** and broad-spectrum efficacy against generalized seizures, including those seen in **juvenile myoclonic epilepsy (JME)** [1]. - It can be used as **monotherapy** and has a generally well-tolerated side effect profile [1], making it a suitable long-term option.*Carbamazepine* - **Carbamazepine** is primarily effective for **focal (partial) seizures** and is generally not recommended for **generalized epilepsy syndromes** like JME due to the risk of worsening myoclonic or absence seizures. - It also has significant **teratogenic risks**, including neural tube defects, making it unsuitable for women of childbearing age when safer alternatives exist [2].*Phenytoin* - **Phenytoin** is effective for focal and tonic-clonic seizures but can **exacerbate myoclonic seizures** in JME. - It carries a significant risk of **teratogenicity**, including fetal hydantoin syndrome, making it an inappropriate choice for women of childbearing potential [2].*Zonisamide* - **Zonisamide** is a broad-spectrum antiepileptic drug, but it is often reserved as an **add-on therapy** for refractory epilepsy rather than a first-line monotherapy, particularly if there are safer and more established first-line options. - While generally considered less teratogenic than valproate, its safety profile in pregnancy has fewer established data compared to levetiracetam.
Question 4: Use of folic acid to prevent congenital malformations should be best initiated:
- A. During 1st trimester of pregnancy
- B. During 2nd trimester of pregnancy
- C. During 3rd trimester of pregnancy
- D. Before conception (Correct Answer)
Explanation: ***Before conception*** - **Neural tube defects (NTDs)**, such as spina bifida and anencephaly, occur very early in pregnancy, often before a woman even knows she is pregnant. - Adequate folate levels are crucial for **neural tube closure**, which happens between 21 and 28 days after conception. Therefore, supplementation needs to start before this period. *During 1st trimester of pregnancy* - While still helpful, initiating folic acid during the first trimester might be **too late** to prevent all NTDs. - The critical period for neural tube formation has largely passed, meaning the **maximum preventive effect** may not be achieved. *During 2nd trimester of pregnancy* - This is **too late** for primary prevention of NTDs, as neural tube closure is completed in the first few weeks of gestation. - At this stage, folic acid supplementation would primarily benefit the ongoing **fetal growth and development**, but not the prevention of NTDs. *During 3rd trimester of pregnancy* - This timing is **ineffective** for the prevention of congenital malformations like NTDs, which have already occurred or been avoided by this point. - Folic acid at this stage primarily supports continued fetal growth and maternal health, but offers no additional benefit regarding **early developmental defects**.
Question 5: A pregnant woman is diagnosed with Graves' disease. The most appropriate therapy for her would be:
- A. Radioiodine therapy
- B. Total thyroidectomy
- C. Carbimazole parenteral
- D. Propylthiouracil oral (Correct Answer)
Explanation: ***Propylthiouracil oral*** - **Propylthiouracil (PTU)** is the preferred antithyroid drug during the **first trimester** of pregnancy due to a lower risk of teratogenicity compared to methimazole/carbimazole [1]. - It works by inhibiting both the synthesis of thyroid hormones and the peripheral conversion of **T4 to T3**. *Radioiodine therapy* - **Radioactive iodine** is absolutely contraindicated in pregnancy as it can cross the placenta and cause **fetal hypothyroidism or athyreosis**. - It leads to permanent destruction of the thyroid gland and is not suitable for a temporary condition in a pregnant woman. *Total thyroidectomy* - While thyroidectomy can be considered for Graves' disease in pregnancy, it is generally reserved for cases where antithyroid drugs are not tolerated or ineffective, or for very large goiters causing compressive symptoms. - It carries risks associated with **surgery and anesthesia** during pregnancy, and requires **lifelong thyroid hormone replacement**. *Carbimazole parenteral* - **Carbimazole** (which is metabolized to methimazole) is generally avoided in the **first trimester** due to an increased risk of teratogenicity, particularly **aplasia cutis**, omphalocele, and choanal atresia [1]. - While it can be used in the second and third trimesters, **PTU is preferred in the first trimester**, and carbimazole is not typically administered parenterally.
Question 6: Which of the following conditions is least likely to be inherited in a familial manner?
- A. Factor V Leiden mutation (Correct Answer)
- B. Hemophilia
- C. Sickle cell anemia
- D. Acquired thrombotic thrombocytopenic purpura (TTP)
Explanation: ***Thalassemia*** - Thalassemia is a **genetic blood disorder** caused by mutations in hemoglobin genes [1], but biomarkers for diagnosis can sometimes arise **de novo**. - It exhibits **incomplete penetrance** and variable expressivity, meaning not all family members may express the trait despite sharing genes. *Hemophilia* - Hemophilia is a **X-linked recessive** disorder predominantly affecting males, passed from carrier mothers to sons [2]. - The condition leads to **deficiencies in blood clotting factors**, which are inherited in a recognizable familial pattern, though about 30% of patients have no family history due to new mutations [2]. *Factor V Leiden mutation* - Factor V Leiden is an **autosomal dominant** genetic mutation leading to increased clotting risk, often inherited from affected parents. - It presents as a familial tendency towards **venous thromboembolism**, clearly identifying its transmission. *Sickle cell anemia* - Sickle cell anemia is an **autosomal recessive** disorder, requiring two copies of the mutated gene for expression, commonly inherited within families [1]. - It leads to characteristic **sickle-shaped red blood cells**, with a clear familial pattern of inheritance [1]. It is important to distinguish that **hereditary disorders** are by definition transmitted through generations and are therefore **familial**.
Question 7: After taking MMR live vaccine, conception should not occur within ?
- A. 4 weeks (Correct Answer)
- B. 8 weeks
- C. 2 weeks
- D. 10 weeks
Explanation: ***4 weeks*** - The **MMR (measles, mumps, and rubella) vaccine** is a **live attenuated vaccine**, meaning it contains weakened forms of the viruses. - To minimize any theoretical risk of congenital rubella syndrome, women are advised to **avoid conception for at least 4 weeks** (or one month) after receiving the MMR vaccine. *2 weeks* - This period is generally considered too short for ensuring the complete clearance of the attenuated live virus from the woman's system before conception. - The standard recommendation for live attenuated vaccines like MMR is typically longer due to potential, though rare, viral transmission risks to the fetus. *8 weeks* - While a longer waiting period like 8 weeks would certainly be safe, it is **not the minimum recommended duration** by public health guidelines. - Waiting 4 weeks (one month) is sufficient and a more practical guideline for most women planning conception. *10 weeks* - This duration is significantly longer than the standard recommendation and is not necessary to ensure safety after an MMR vaccination. - The 4-week guideline balances safety with practicality for reproductive planning.
Question 8: 34 week primigravida punjabi khatri comes with history of consanguineous marriage, with history of repeated blood transfusion to her sibling since 8 months of age. The first diagnostic test is -
- A. HPLC
- B. Bone marrow
- C. Blood smear
- D. Hb electrophoresis (Correct Answer)
Explanation: ***Hb electrophoresis*** - The patient's history of **consanguineous marriage**, a sibling requiring **repeated blood transfusions** since 8 months of age, and Punjabi Khatri ethnicity strongly suggest a **hemoglobinopathy**, likely **beta-thalassemia major or intermedia**. - **Hemoglobin electrophoresis** is the traditional gold standard for definitive diagnosis of various hemoglobin variants and thalassemia types, identifying and characterizing abnormal hemoglobin patterns (e.g., elevated HbF, HbA2). - It remains a primary diagnostic test for hemoglobinopathies, particularly useful for pattern recognition of various thalassemia syndromes. *HPLC* - **High-performance liquid chromatography (HPLC)** is an equally valid and increasingly preferred method for diagnosing hemoglobinopathies, offering automated, precise quantification of hemoglobin fractions (HbA, HbA2, HbF). - In modern practice, HPLC is often used as a first-line screening tool due to its accuracy, reproducibility, and ability to provide quantitative data crucial for thalassemia diagnosis. - Both HPLC and Hb electrophoresis are acceptable diagnostic approaches; the choice between them depends on laboratory availability and practice patterns. For this 2013 exam, Hb electrophoresis was considered the traditional first diagnostic test. *Blood smear* - A **peripheral blood smear** would show morphological changes like **microcytic hypochromic red blood cells**, **target cells**, **anisopoikilocytosis**, and **nucleated RBCs**, which are suggestive of thalassemia. - These findings are indicative but non-specific and require confirmatory tests like hemoglobin electrophoresis or HPLC to identify the specific hemoglobin disorder and establish a definitive diagnosis. *Bone marrow* - A **bone marrow** examination would show **erythroid hyperplasia** due to increased ineffective erythropoiesis in thalassemia but is an invasive procedure and not the initial diagnostic test for hemoglobinopathies. - It provides details about cellularity and maturation but does not directly identify hemoglobin abnormalities, making it unsuitable as the first diagnostic step in suspected hemoglobinopathies.
Question 9: A woman presents with a history of recurrent abortions at 8,11 , and 22 weeks, with normal fetal cardiac activity in all three pregnancies. She also has a history of preeclampsia in her last pregnancy. What is the most probable cause?
- A. Syphilis
- B. Gestational Diabetes Mellitus (GDM)
- C. TORCH infections
- D. Antiphospholipid Antibody Syndrome (APLA) (Correct Answer)
Explanation: ***Antiphospholipid Antibody Syndrome (APLA)*** - The presentation of **recurrent abortions** (especially with normal fetal cardiac activity) and a history of **preeclampsia** is highly characteristic of Antiphospholipid Antibody Syndrome (APLA). - In APLA, antibodies cause **thrombosis** in the placental vasculature, leading to placental insufficiency, fetal loss, and complications like preeclampsia. *Syphilis* - While syphilis can cause fetal loss, it typically presents with **hydrops fetalis**, hepatosplenomegaly, and bone abnormalities, rather than recurrent losses with normal cardiac activity in the early stages. - Untreated syphilis usually leads to congenital syphilis or stillbirths later in pregnancy, not necessarily early recurrent abortions with good fetal heart tones. *Gestational Diabetes Mellitus (GDM)* - GDM is associated with complications like **macrosomia**, polyhydramnios, and an increased risk of shoulder dystocia, but it is not a direct cause of recurrent early and mid-trimester abortions with normal fetal cardiac activity. - While poorly controlled diabetes can affect fetal development and pregnancy outcomes, it does not typically manifest as recurrent unexplained fetal demise with this specific presentation. *TORCH infections* - TORCH infections (Toxoplasmosis, Other [syphilis, varicella-zoster, parvovirus B19], Rubella, Cytomegalovirus, and Herpes simplex virus) can cause congenital anomalies and fetal death. - However, they would usually present with specific fetal abnormalities, signs of infection, or hydrops, and not typically with recurrent, apparently healthy fetal losses followed by preeclampsia, as often seen in APLA.
Question 10: A 24-year-old woman presents with abnormal vaginal discharge. Wet mount shows motile trichomonads. Her male partner is asymptomatic. Which of the following is the most appropriate management for her partner?
- A. Treat regardless of symptoms (Correct Answer)
- B. No treatment unless symptoms develop
- C. Test before treating
- D. Monitor without intervention
Explanation: ***Treat regardless of symptoms*** - **Trichomoniasis** is a sexually transmitted infection, and partners of infected individuals should be treated even if they are asymptomatic to prevent **reinfection** and further transmission. - **Male partners** often carry the infection asymptomatically, acting as a reservoir for transmission. *No treatment unless symptoms develop* - This approach would lead to **persistent infection** in the male partner and an increased risk of **reinfection** for the female patient. - Asymptomatic carriers can still transmit the infection, undermining the treatment of the symptomatic partner. *Test before treating* - While testing is possible, current guidelines recommend **presumptive treatment** for male partners of women diagnosed with trichomoniasis to ensure effective eradication and prevent recurrence. - The **sensitivity** of diagnostic tests for trichomoniasis in men can be lower than in women, potentially leading to false negatives. *Monitor without intervention* - Monitoring without intervention is inadequate as it allows the male partner to remain an **infectious source** and risks **recurrent infection** for the female patient. - The goal is to break the chain of transmission and fully cure both partners.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free